Edition:
United States

Retrophin Inc (RTRX.OQ)

RTRX.OQ on NASDAQ Stock Exchange Global Market

23.86USD
18 Aug 2017
Change (% chg)

$0.22 (+0.93%)
Prev Close
$23.64
Open
$23.48
Day's High
$24.25
Day's Low
$23.47
Volume
111,999
Avg. Vol
114,854
52-wk High
$24.54
52-wk Low
$15.57

Latest Key Developments (Source: Significant Developments)

Retrophin reports Q2 loss per share $0.34
Wednesday, 9 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Retrophin Inc :Retrophin reports second quarter 2017 financial results.Q2 loss per share $0.34.Q2 revenue $39 million versus I/B/E/S view $37.4 million.Q2 adjusted non-gaap earnings per share $0.03.Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Protocol design for pivotal phase 3 trial of sparsentan in fsgs complete.Retrophin Inc - company reiterates its full-year 2017 guidance of $150.0 to $160.0 million in net product sales.  Full Article

Retrophin commences patient dosing in international, registrational phase 3 trial of RE-024 in PKAN
Tuesday, 25 Jul 2017 08:00am EDT 

July 25 (Reuters) - Retrophin Inc :Retrophin commences patient dosing in international, registrational phase 3 trial of re-024 in pkan.Retrophin inc -announced that first patient has been dosed in fort study registrational phase 3 clinical trial assessing safety and efficacy of re-024.  Full Article

Retrophin Q1 loss per share $0.29
Thursday, 4 May 2017 04:01pm EDT 

May 4 (Reuters) - Retrophin Inc ::Retrophin reports first quarter 2017 financial results.Q1 loss per share $0.29.Q1 revenue $34 million versus I/B/E/S view $36.2 million.Q1 adjusted non-gaap earnings per share $0.01.Q1 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.Retrophin Inc says company reiterates its full-year 2017 guidance of $150.0 to $160.0 million in net product sales.Fy2017 revenue view $155.8 million -- Thomson Reuters I/B/E/S.  Full Article

Retrophin initiates a plan to consolidate its operations to its corporate headquarters in San Diego
Wednesday, 8 Mar 2017 05:17pm EST 

Retrophin Inc : On March 7, 2017, company initiated a plan to consolidate its operations to its corporate headquarters in San Diego, CA . Intends to close its Cambridge, MA office by end of 2017 . As part of plan, select employees will relocate from Cambridge, MA to San Diego headquarters by end of 2017-SEC filing . Estimates it could incur up to $4.5 million in employee related separation and transitional cash charges as a result of the consolidation .As part of plan, replacements for other functions will be hired during course of 2017.  Full Article

Retrophin Q4 loss per share $0.23
Wednesday, 1 Mar 2017 04:01pm EST 

Retrophin Inc : Retrophin inc says phase 3 trial of sparsentan in fsgs to initiate in second half of 2017 . Retrophin inc - phase 3 trial of sparsentan in fsgs to initiate in second half of 2017 . Retrophin inc - interim analysis of proteinuria to serve as basis for nda filing for accelerated approval . Retrophin inc - net product sales for q4 of 2016 were $37.3 million, compared to net product sales of $30.4 million for same period in 2015 . Retrophin inc - company expects full year 2017 net product sales to be in range of $150.0 to $160.0 million . Retrophin provides sparsentan regulatory update; reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.23 . Q4 adjusted non-gaap earnings per share $0.00 .Q4 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

Retrophin reports Q3 loss per share $1.00
Thursday, 3 Nov 2016 04:01pm EDT 

Retrophin Inc : Trial evaluating efficacy of re-024 in pantothenate kinase-associated neurodegeneration remains on track to initiate before year-end 2016 . Net product sales for q3 of 2016 were $33.9 million, compared to $28.0 million for same period in 2015 . Q3 earnings per share view $0.38, revenue view $34.8 million -- Thomson Reuters I/B/E/S . Retrophin reports third quarter 2016 financial results . Q3 adjusted non-gaap loss per share $0.09 . Q3 loss per share $1.00 .Q3 revenue rose 21 percent.  Full Article

Retrophin considering acquisition of Raptor Pharmaceutical- Bloomberg
Wednesday, 17 Aug 2016 08:00pm EDT 

:Retrophin Inc considering acquisition of Raptor Pharmaceutical Corp - Bloomberg, citing sources.  Full Article

Retrophin posts Q2 adj EPS $0.07, net product sales $33.2 mln
Thursday, 4 Aug 2016 04:01pm EDT 

Retrophin Inc : Q2 adjusted non-gaap earnings per share $0.07 . Q2 revenue rose 38 percent . Retrophin reports second quarter 2016 financial results . Q2 loss per share $0.37 . Retrophin inc says net product sales for q2 of 2016 were $33.3 million, compared to net product sales of $24.1 million for same period in 2015 .Says remains on track to initiate its efficacy trial evaluating RE 024 in pkan during second half of 2016.  Full Article

Martin Shkreli faces June 2017 trial date in fraud case
Thursday, 14 Jul 2016 02:23pm EDT 

: Trial date set by federal judge at hearing in Brooklyn, New York.  Full Article

Retrophin buys liquid formulation of Ursodeoxycholic acid
Monday, 20 Jun 2016 04:30pm EDT 

Retrophin Inc : Made an upfront payment of $0.5 million and will make future payments of up to $23.5 million based on cumulative sales milestones . Intends to file a new drug application with U.S. FDA for liquid formulation of ursodeoxycholic acid in 2017 . Asklepion will be eligible to receive incremental milestone payments of up to $35.0 million upon successful development and commercialization . Will assume all future program costs and pay asklepion tiered royalties on future product sales .Retrophin acquires liquid formulation of ursodeoxycholic acid.  Full Article

BRIEF-Retrophin reports Q2 loss per share $0.34

* Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S